2002
DOI: 10.1067/mic.2002.121153
|View full text |Cite
|
Sign up to set email alerts
|

Pseudomonas aeruginosa infections in a neonatal intensive care unit

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
11
0

Year Published

2005
2005
2025
2025

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 19 publications
(11 citation statements)
references
References 41 publications
0
11
0
Order By: Relevance
“…[12][13][14][15] These measures frequently involve cohort isolation, meticulous hand hygiene 6 and barrier protection of the care team and parents by use of gloves and gowns. Pharmacologic agents have been used with some success, particularly with intranasal mupirocin for methicillin resistant Staphylococcus aureus.…”
Section: Discussionmentioning
confidence: 99%
“…[12][13][14][15] These measures frequently involve cohort isolation, meticulous hand hygiene 6 and barrier protection of the care team and parents by use of gloves and gowns. Pharmacologic agents have been used with some success, particularly with intranasal mupirocin for methicillin resistant Staphylococcus aureus.…”
Section: Discussionmentioning
confidence: 99%
“…Pseudomonas aeruginosa is one of the main organisms responsible for drug-resistant health care-associated infections [1][2][3] . Its ability to survive and replicate in hospital in a wide range of ecological niches, sometimes hostile to other microorganisms, may create tenacious environmental reservoirs, such as faucets, tap water, sinks, respiratory-therapy equipment and even detergents and disinfectants [4,5] .…”
Section: Introductionmentioning
confidence: 99%
“…Well known as a multiresistant organism, it is posing new therapeutic and public health challenges because of the emergence and widespread dissemination of strains producing metallo-β-lactamases (MBL). Indeed, these enzymes can confer resistance to all β-lactams except monobactams and are not susceptible to the clinically available β-lactamase inhibitors [3,6] . Several types of these enzymes have been detected; namely, IMP, VIM, SPM, GIM and SIM, mostly in P aeruginosa and other Gram-negative nonfermenters [7] .…”
Section: Introductionmentioning
confidence: 99%
“…Some strains can produce biofi lm containing a mucoid polysaccharide called alginate which makes them less suscep ble to an microbials. Furthermore, Exotoxin A and Exoenzyme S are the products produced by pseudomonas which are responsible for the development of sepsis syndrome by the organism 9 . The organism also produce plasmid associated beta lactamases which render the organism mul drug resistant.…”
Section: Discussionmentioning
confidence: 99%